Inicio / Hematología / Abstracts de hematología / Tyrosine kinase inhibitor…

Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance

0 / 5 (0 votos)
Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance

The Lancet Haematology

Fecha de publicación: 1 december 2018

DOI: https://doi.org/10.1016/S2352-3026(18)30181-9

Autores: Oliver Ottmann

Background: Before the advent of tyrosine kinase inhibitor (TKI) therapy, Philadelphia chromosome-positive acute lymphoblastic leukaemia had an exceptionally poor prognosis and was a clear indication for allogeneic haemopoietic stem cell transplantation (HSCT). Adding TKIs to frontline therapy improves survival, with transplantation in paediatric patients increasingly reserved for those with poor response.

Seguir leyendo

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.